Recombinant antibody against human insulin-like growth factor
US7498415B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 24, 2004 |
| Grant date | Mar 3, 2009 |
| Priority date | — |
| Expiry date | Sep 24, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
It is demanded that pharmaceutical agents for therapeutic treatment of diseases such as cancer, acromegaly and diabetic complications, of which IGF is involved in the progress of the conditions.The present invention provides a recombinant antibody or an antibody fragment thereof which specifically binds to human insulin-like growth factor-I (hereinafter referred to as hIGF-I) and human insulin-like growth factor-II (hereinafter referred to as hIGF-II) to inhibit the biological activities of human IGF-I and human IGF-II, a transformant producing the antibody or the antibody fragment thereof, a process for producing the antibody or the antibody fragment thereof, and a medicament comprising the antibody or the antibody fragment thereof as the active ingredient therein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.